MA27038A1 - Compositions pharmaceutiques d'adsorbats d'un medicament amorphe - Google Patents
Compositions pharmaceutiques d'adsorbats d'un medicament amorpheInfo
- Publication number
- MA27038A1 MA27038A1 MA27435A MA27435A MA27038A1 MA 27038 A1 MA27038 A1 MA 27038A1 MA 27435 A MA27435 A MA 27435A MA 27435 A MA27435 A MA 27435A MA 27038 A1 MA27038 A1 MA 27038A1
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical compositions
- adsorbates
- medicinal product
- amorphous
- amorphous medicinal
- Prior art date
Links
- 239000002156 adsorbate Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30026001P | 2001-06-22 | 2001-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27038A1 true MA27038A1 (fr) | 2004-12-20 |
Family
ID=23158346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA27435A MA27038A1 (fr) | 2001-06-22 | 2003-12-11 | Compositions pharmaceutiques d'adsorbats d'un medicament amorphe |
Country Status (29)
Country | Link |
---|---|
US (3) | US20030054037A1 (fr) |
EP (2) | EP2275091A1 (fr) |
JP (1) | JP4547148B2 (fr) |
KR (2) | KR100759635B1 (fr) |
CN (1) | CN1523979A (fr) |
AT (1) | ATE486586T1 (fr) |
AU (1) | AU2002302903B2 (fr) |
BG (1) | BG108489A (fr) |
BR (1) | BR0210519A (fr) |
CA (1) | CA2448825C (fr) |
CR (1) | CR7167A (fr) |
CZ (1) | CZ20033456A3 (fr) |
DE (1) | DE60238193D1 (fr) |
EA (1) | EA006777B1 (fr) |
EC (1) | ECSP034895A (fr) |
EE (1) | EE200400034A (fr) |
HU (1) | HUP0400281A3 (fr) |
IL (1) | IL158771A0 (fr) |
IS (1) | IS7018A (fr) |
MA (1) | MA27038A1 (fr) |
MX (1) | MXPA03010165A (fr) |
NO (1) | NO20035498D0 (fr) |
NZ (1) | NZ529490A (fr) |
OA (1) | OA12625A (fr) |
PL (1) | PL367674A1 (fr) |
SK (1) | SK15742003A3 (fr) |
TN (1) | TNSN03138A1 (fr) |
WO (1) | WO2003000238A1 (fr) |
ZA (1) | ZA200308735B (fr) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0307332A (pt) * | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol |
ES2305434T3 (es) | 2002-02-01 | 2008-11-01 | Pfizer Products Inc. | Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas. |
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
US7838029B1 (en) * | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
WO2005011635A2 (fr) | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Compositions pharmaceutiques a base d'adsorbats de medicaments amorphes et de produits aptes a former des microphases lipophiles |
US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
WO2005023225A1 (fr) * | 2003-09-05 | 2005-03-17 | Ranbaxy Laboratories Limited | Adsorbat de cilostazol |
ES2281594T3 (es) * | 2003-11-18 | 2007-10-01 | Helm Ag | Procedimiento para la preparacion de adsorbatos de atorvastatina en polvo de flujo libre. |
ES2274386T3 (es) * | 2004-02-06 | 2007-05-16 | Helm Ag | Preparaciones farmaceuticas que contienen tibolona amorfa. |
MY142989A (en) * | 2004-03-10 | 2011-02-14 | Bayer Schering Pharma Ag | Stabilised supersaturated solids of lipophilic drugs |
JP2008511607A (ja) | 2004-08-31 | 2008-04-17 | ファイザー・プロダクツ・インク | 低溶解性薬物および重合体を含む医薬投与剤形 |
GB2419094A (en) * | 2004-10-12 | 2006-04-19 | Sandoz Ag | Pharmaceutical composition of unpleasnt tasing active substances |
DE102004055229A1 (de) * | 2004-11-17 | 2006-05-18 | Heidelberger Druckmaschinen Ag | Zustandsabhängige Absicherung von Maschinen |
WO2006069162A1 (fr) * | 2004-12-20 | 2006-06-29 | Reddy Us Therapeutics, Inc. | Nouveaux composes heterocycliques et leurs compositions pharmaceutiques |
US8604055B2 (en) * | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
CN101443006B (zh) * | 2004-12-31 | 2012-10-10 | 雷迪美国治疗股份有限公司 | 作为cetp抑制剂的新颖的苄胺衍生物 |
US20090005384A1 (en) * | 2005-01-25 | 2009-01-01 | Kowa Co., Ltd | Method for Producing Adsorptive Porous Body |
EP1855652B1 (fr) | 2005-01-28 | 2015-12-02 | Bend Research, Inc | Deshydratation de particules contenant un medicament |
US8617604B2 (en) * | 2005-02-03 | 2013-12-31 | Bend Research, Inc. | Pharmaceutical compositions with enhanced performance |
WO2006085217A2 (fr) * | 2005-02-08 | 2006-08-17 | Pfizer Products Inc. | Adsorbes solides de medicaments hydrophobes |
EP1767194A1 (fr) * | 2005-06-09 | 2007-03-28 | Helm AG | Procédé pour la préparation d'adsorbats de drospirenone |
US8398576B2 (en) * | 2007-04-02 | 2013-03-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Removal of contrast agents from blood |
CA2681829A1 (fr) * | 2007-04-03 | 2008-10-16 | Dr. Reddy's Laboratories Ltd. | Formes solides de pemetrexed |
EP1987816A1 (fr) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate d'un sel de rasagiline en combinaison avec un agent inactive soluble dans l'eau |
JP6073043B2 (ja) | 2007-08-21 | 2017-02-01 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 医薬品適用のための熱−動力学的混合 |
EP2072042A1 (fr) * | 2007-12-21 | 2009-06-24 | Lek Pharmaceuticals D.D. | Ingrédient pharmaceutique actif sur support solide amorphe et avec solubilité améliorée |
WO2009113522A1 (fr) * | 2008-03-11 | 2009-09-17 | あすか製薬株式会社 | Dispersion solide, compositions pharmaceutiques comprenant celle-ci, et procédés de production associés |
BRPI0912099A2 (pt) * | 2008-05-30 | 2015-10-06 | Eisai R&D Man Co Ltd | preparação percutaneamente absorvível |
CN102227244A (zh) * | 2008-10-02 | 2011-10-26 | 匹兹堡大学-属高等教育联邦体系 | 用于治疗全身性炎症的吸附剂聚合物的施用 |
JP2012506904A (ja) * | 2008-10-28 | 2012-03-22 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | 難水溶性成分のためのメソ多孔性材料賦形剤 |
KR101004205B1 (ko) | 2008-12-17 | 2010-12-24 | 동아제약주식회사 | 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물 |
JPWO2010092925A1 (ja) * | 2009-02-12 | 2012-08-16 | あすか製薬株式会社 | 固体分散体とその医薬組成物、並びにそれらの製造方法 |
WO2010102066A1 (fr) * | 2009-03-05 | 2010-09-10 | Bend Research, Inc. | Poudre de polymère de dextrane destinée à l'administration de produits pharmaceutiques par inhalation |
PT3130396T (pt) | 2009-03-27 | 2021-05-12 | Bend Res Inc | Processo de secagem por pulverização |
EP2238979A1 (fr) * | 2009-04-06 | 2010-10-13 | LEK Pharmaceuticals d.d. | Ingrédient pharmaceutique actif absorbé sur un support solide |
US20120087978A1 (en) | 2009-06-16 | 2012-04-12 | Bristol-Myers Squibb Company | Dosage forms of apixaban |
EP2366378A1 (fr) | 2010-03-01 | 2011-09-21 | Dexcel Pharma Technologies Ltd. | Formulations de donépézil à libération prolongée |
WO2011110662A1 (fr) * | 2010-03-11 | 2011-09-15 | Danmarks Tekniske Universitet | Composés supportés biologiquement actifs |
US20130108701A1 (en) | 2010-05-25 | 2013-05-02 | Krishna Murthy Bhavanasi | Solid Dosage Forms of Antipsychotics |
EP2611530B1 (fr) | 2010-09-03 | 2019-01-16 | Bend Research, Inc. | Appareil de séchage par atomisation et procédés d'utilisation de cet appareil |
US8815294B2 (en) | 2010-09-03 | 2014-08-26 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives and a carrier material |
US9084976B2 (en) | 2010-09-03 | 2015-07-21 | Bend Research, Inc. | Spray-drying apparatus and methods of using the same |
WO2012040502A1 (fr) | 2010-09-24 | 2012-03-29 | Bend Research, Inc. | Procédé et appareil de séchage par pulvérisation à température élevée |
TWI590821B (zh) * | 2011-01-18 | 2017-07-11 | 輝瑞有限公司 | 固體分子分散液 |
US9084727B2 (en) | 2011-05-10 | 2015-07-21 | Bend Research, Inc. | Methods and compositions for maintaining active agents in intra-articular spaces |
CN103732216A (zh) * | 2011-08-16 | 2014-04-16 | 默沙东公司 | 无机基质和有机聚合物组合用于制备稳定的无定形分散体的用途 |
JP5964965B2 (ja) | 2011-08-18 | 2016-08-03 | ドクター レディズ ラボラトリーズ リミテッド | コレステリルエステル転送タンパク質(cetp)インヒビターとしての置換複素環式アミン化合物 |
KR101803866B1 (ko) | 2011-09-27 | 2017-12-04 | 닥터 레디스 레보러터리즈 리미티드 | 동맥경화증 치료에 유용한 콜레스테릴 에스테르-전달 단백질(cetp) 억제제로서 5-벤질아미노메틸-6-아미노피라졸로[3,4-b]피리딘 유도체 |
US20160346207A1 (en) * | 2014-02-05 | 2016-12-01 | Lek Pharmaceuticals D.D. | Solid Pharmaceutical Compositions Of Androgen Receptor Antagonists |
WO2016067132A1 (fr) | 2014-10-31 | 2016-05-06 | Bend Research Inc. | Procédé de formation de domaines actifs dispersés dans une matrice |
WO2016204058A1 (fr) * | 2015-06-15 | 2016-12-22 | 住友化学株式会社 | Procédé de fabrication d'élément électroluminescent organique |
CN113476408A (zh) * | 2021-07-23 | 2021-10-08 | 兆科药业(广州)有限公司 | 一种苯丁酸甘油酯颗粒剂及其制备方法与应用 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1146866A (fr) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Procede de production d'un compose pharmaceutique a liberation continue sous forme solide |
FR2525108B1 (fr) * | 1982-04-19 | 1989-05-12 | Elan Corp Ltd | Medicaments a haut degre de solubilite et procede pour leur obtention |
JPS5942313A (ja) * | 1982-09-01 | 1984-03-08 | Teijin Ltd | ポリビニルポリピロリドンを用いた製剤 |
EP0129893B1 (fr) * | 1983-06-28 | 1991-09-04 | Takeda Chemical Industries, Ltd. | Mélange broyé |
US4581232A (en) * | 1983-07-20 | 1986-04-08 | Warner-Lambert Company | Magnesium trisilicate suitable for preparation of medicament adsorbates |
IE63321B1 (en) | 1986-02-03 | 1995-04-05 | Elan Corp Plc | Drug delivery system |
US4716033A (en) * | 1986-03-27 | 1987-12-29 | Warner-Lambert Company | Medicament adsorbates with surfactant and their preparation |
US4717565A (en) * | 1986-03-27 | 1988-01-05 | Warner-Lambert Company | Process for the preparation of medicament adsorbates |
US4711774A (en) * | 1986-03-27 | 1987-12-08 | Warner-Lambert Company | Medicament adsorbates with complex magnesium aluminum silicate and their preparation |
US5015479A (en) * | 1987-02-02 | 1991-05-14 | Seamus Mulligan | Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine |
US4835186A (en) * | 1987-06-15 | 1989-05-30 | American Home Products Corporation | Spray dried ibuprofen |
IT1216570B (it) * | 1988-04-08 | 1990-03-08 | Vectorpharma Int | Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione. |
IT1227626B (it) * | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
IE60458B1 (en) | 1989-10-26 | 1994-07-13 | Elan Corp Plc | Enhanced bioavailability adsorbates |
US5300302A (en) * | 1990-10-04 | 1994-04-05 | Nestec S.A. | Pharmaceutical composition in gel form in a dispensing package |
US5559158A (en) * | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
US5626878A (en) * | 1995-01-10 | 1997-05-06 | Warner Lambert Company | Reduction of electrostatic forces between magnesium trisilicate adsorbates |
SI9500059A (sl) | 1995-02-23 | 1996-08-31 | Lek Tovarna Farmacevtskih | Postopek za pripravo trdnih površinskih disperzij amorfnih, v vodnih medijih slabo topnih učinkovin in njihova uporaba |
CA2218173A1 (fr) | 1995-04-14 | 1996-10-17 | The Administrators Of The Tulane Educational Fund | Analogues du facteur liberant l'hormone de croissance |
AU6378796A (en) * | 1995-06-06 | 1996-12-24 | Warner-Lambert Company | Ranitidine salts on magnesium trisilicate as an adsorbate |
DE19532061A1 (de) * | 1995-08-31 | 1997-03-06 | Bayer Ag | N-Sulfonyliminodithioverbindungen |
DE19610932A1 (de) | 1996-03-20 | 1997-09-25 | Bayer Ag | 2-Aryl-substituierte Pyridine |
DE19627419A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Cycloalkano-pyridine |
HRP970330B1 (en) | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
DE19627430A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Bicyclisch kondensierte Pyridine |
US6207671B1 (en) | 1996-07-08 | 2001-03-27 | Bayer Aktiengesellschaft | Cycloalkano-pyridines |
AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
DE19704244A1 (de) | 1997-02-05 | 1998-08-06 | Bayer Ag | 5-Hydroxy-alkyl substituierte Phenyle |
DE19704243A1 (de) | 1997-02-05 | 1998-08-06 | Bayer Ag | Neue 2-Amino-substituierte Pyridine |
JP2894445B2 (ja) | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Cetp活性阻害剤として有効な化合物 |
EP0966443B1 (fr) | 1997-02-26 | 2009-01-28 | Pfizer Inc. | Derives amines de l'acide heteroaryle-hexanoique, leur preparation, et leur utilisation comme inhibiteurs selectifs du mip-1 alpha par fixation a son recepteur ccr1 |
DE19709125A1 (de) | 1997-03-06 | 1998-09-10 | Bayer Ag | Substituierte Chinoline |
PT901786E (pt) * | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
AU9297798A (en) | 1997-09-16 | 1999-04-05 | G.D. Searle & Co. | Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity |
DE19832159A1 (de) | 1997-09-18 | 1999-03-25 | Bayer Ag | Substituierte Tetrahydro-naphthaline |
MA24643A1 (fr) | 1997-09-18 | 1999-04-01 | Bayer Ag | Tetrahydro-naphtalenes substitues et composes analogues |
DE19741051A1 (de) | 1997-09-18 | 1999-03-25 | Bayer Ag | Hetero-Tetrahydrochinoline |
DE19741399A1 (de) | 1997-09-19 | 1999-03-25 | Bayer Ag | Tetrahydrochinoline |
DE19741400A1 (de) | 1997-09-19 | 1999-03-25 | Bayer Ag | Benzyl-biphenyle |
CA2304763A1 (fr) * | 1997-09-29 | 1999-04-08 | Pei Han | Composition de fagopyrum cymosum (trev.) meisn, son procede de preparation et d'analyse et ses utilisations |
HUP0100832A3 (en) | 1998-02-05 | 2002-03-28 | Pfizer Prod Inc | Quinoxaline and quinoline carboxamide derivatives, their use and the pharmaceutical compositions containing them |
AU3285499A (en) | 1998-02-13 | 1999-08-30 | G.D. Searle & Co. | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity |
JPH11246404A (ja) | 1998-03-04 | 1999-09-14 | Taiho Yakuhin Kogyo Kk | 吸収を改善した医薬組成物 |
US20010025046A1 (en) * | 1999-06-24 | 2001-09-27 | Rong(Ron) Liu | Self-emulsifying systems containing anticancer medicament |
AU5486899A (en) * | 1998-08-13 | 2000-03-06 | Cima Labs, Inc. | Microemulsions as solid dosage forms for oral administration |
US6376481B2 (en) * | 1998-09-02 | 2002-04-23 | Mcneil-Ppc, Inc. | Sterol esters in tableted solid dosage forms |
GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
US6147089A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6147090A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6140342A (en) | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
ATE361273T1 (de) | 1998-09-25 | 2007-05-15 | Monsanto Co | Polycyclische aryl und heteroaryl substituierte tertiäre heteroalkylamine, für die hemmung der aktivität des cholesteryl-ester-transfer-proteins |
JP2002525350A (ja) | 1998-09-25 | 2002-08-13 | モンサント カンパニー | コレステロールエステル輸送タンパク質活性阻害に有効な置換されたn−脂肪族−n−芳香族第三級ヘテロアルキルアミン |
EP1027887B1 (fr) * | 1999-02-10 | 2008-08-13 | Pfizer Products Inc. | Dispositif pour la libération du principe actif contrôlée par la matrice |
PT1165051E (pt) * | 1999-03-19 | 2003-11-28 | Ranbaxy Lab Ltd | Processo para a preparacao de uma forma de dosagem oral biodisponivel de cefuroxima axetil |
KR100342943B1 (ko) * | 1999-08-04 | 2002-07-02 | 민경윤 | 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물 |
UY26615A1 (es) * | 2000-03-16 | 2001-10-25 | Pfizer Prod Inc | Inhibidor de la glucogeno fosforilasa. |
AR027656A1 (es) * | 2000-03-16 | 2003-04-09 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa |
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
US6602523B1 (en) * | 2000-08-17 | 2003-08-05 | Technology Holding, Llc. | Composite material and process for increasing bioavailability and activity of a beneficial agent |
US6596262B2 (en) * | 2001-02-15 | 2003-07-22 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
-
2002
- 2002-05-21 NZ NZ529490A patent/NZ529490A/en unknown
- 2002-05-21 OA OA1200300326A patent/OA12625A/en unknown
- 2002-05-21 BR BR0210519-5A patent/BR0210519A/pt not_active IP Right Cessation
- 2002-05-21 KR KR1020067021756A patent/KR100759635B1/ko not_active IP Right Cessation
- 2002-05-21 PL PL02367674A patent/PL367674A1/xx not_active Application Discontinuation
- 2002-05-21 MX MXPA03010165A patent/MXPA03010165A/es active IP Right Grant
- 2002-05-21 HU HU0400281A patent/HUP0400281A3/hu unknown
- 2002-05-21 KR KR1020037017032A patent/KR100768766B1/ko not_active IP Right Cessation
- 2002-05-21 EA EA200301279A patent/EA006777B1/ru not_active IP Right Cessation
- 2002-05-21 IL IL15877102A patent/IL158771A0/xx unknown
- 2002-05-21 CA CA002448825A patent/CA2448825C/fr not_active Expired - Lifetime
- 2002-05-21 CN CNA028125037A patent/CN1523979A/zh active Pending
- 2002-05-21 EP EP10175652A patent/EP2275091A1/fr not_active Withdrawn
- 2002-05-21 CZ CZ20033456A patent/CZ20033456A3/cs unknown
- 2002-05-21 AU AU2002302903A patent/AU2002302903B2/en not_active Ceased
- 2002-05-21 EE EEP200400034A patent/EE200400034A/xx unknown
- 2002-05-21 AT AT02730596T patent/ATE486586T1/de not_active IP Right Cessation
- 2002-05-21 EP EP02730596A patent/EP1404302B1/fr not_active Revoked
- 2002-05-21 SK SK1574-2003A patent/SK15742003A3/sk not_active Application Discontinuation
- 2002-05-21 WO PCT/IB2002/001792 patent/WO2003000238A1/fr active IP Right Grant
- 2002-05-21 JP JP2003506885A patent/JP4547148B2/ja not_active Expired - Fee Related
- 2002-05-21 DE DE60238193T patent/DE60238193D1/de not_active Expired - Lifetime
- 2002-05-21 TN TNPCT/IB2002/001792A patent/TNSN03138A1/fr unknown
- 2002-06-17 US US10/173,987 patent/US20030054037A1/en not_active Abandoned
-
2003
- 2003-11-10 IS IS7018A patent/IS7018A/is unknown
- 2003-11-10 ZA ZA200308735A patent/ZA200308735B/en unknown
- 2003-11-25 CR CR7167A patent/CR7167A/es not_active Application Discontinuation
- 2003-12-10 NO NO20035498A patent/NO20035498D0/no not_active Application Discontinuation
- 2003-12-11 MA MA27435A patent/MA27038A1/fr unknown
- 2003-12-11 EC EC2003004895A patent/ECSP034895A/es unknown
- 2003-12-22 BG BG108489A patent/BG108489A/bg unknown
-
2006
- 2006-12-04 US US11/566,408 patent/US8703199B2/en active Active
-
2008
- 2008-07-28 US US12/180,769 patent/US8389006B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27038A1 (fr) | Compositions pharmaceutiques d'adsorbats d'un medicament amorphe | |
DE60325354D1 (de) | Topisch anwendbare pharmazeutische zubereitung | |
CA2395331A1 (fr) | Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees | |
DE3779500D1 (de) | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. | |
WO2005011635A3 (fr) | Compositions pharmaceutiques a base d'adsorbats de medicaments amorphes et de produits aptes a former des microphases lipophiles | |
WO2002036135A3 (fr) | Traitements anti-tumeur efficaces | |
ATE292453T1 (de) | Antivirale arznei | |
ATE291914T1 (de) | Zolmitriptanhaltige arzneizusammensetzungen | |
ATE402691T1 (de) | Pharmazeutische zusammensetzungen zur oralen und topischen verabreichung | |
ATE383868T1 (de) | Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka | |
RS50298B (sr) | Direktno kompresibilna matrica za kontrolisano oslobađanje pojedinačnih dnevnih doza klaritromicina | |
ATE262893T1 (de) | Darreichungsformen zur behandlung von oralen mykosen | |
MY141008A (en) | Oral formulations of deoxypeganine and their uses | |
EP0761209A3 (fr) | Formulations de la ranitidine à libération commandée | |
ATE307131T1 (de) | Phenanthrolin-7-onderivate und ihre therapeutische verwendung | |
GB0201607D0 (en) | Formulation for the administration of medicinal substances | |
NO971574D0 (no) | Medisinmateanordning for tildeling av medisin via munnen særlig beregnet for mindre barn | |
AU3278400A (en) | New use of taxoid derivatives | |
RU2002131677A (ru) | Устройство для стимулирования специфических рефлекторных точек на поверхности тела | |
AU2003202074A1 (en) | Formulation for the administration of medicinal substances | |
ITMI912989A1 (it) | Composizioni farmaceutiche ad uso orale, a base di esteri di gangliosidi, per il trattamento di neuropatie del sistema nervoso periferico | |
ITMI912988A0 (it) | Composizioni farmaceutiche ad uso orale a base di esteri interno di gangliosidi per il trattamento di patologie del sistema nervoso centrale | |
AU2002328763A1 (en) | Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament |